Biomarker assays, analysis and interpretations
Understanding the complexity of the tumour immune microenvironment in tissues from preclinical mouse models through to patients on clinical trial provides valuable information for the drug discovery process.
At HistologiX we offer validated and optimised IHC immuno-oncology biomarker assays, together with next generation quantitative image analysis tools to deliver valuable immunological insight into tumour immune processes. Our robust approach to the identification, quantification, localisation, and spatial relationships of immuno-oncology biomarkers in tumour tissues, and the ability to interpret data from these assays, supports clients in making informed decisions for advancing their immunotherapeutic strategy to market.
Spatial distribution of immune cells within the tumour microenvironment is likely to be as important as the quantitative assessment of immune cell densities. By defining the interface between tumour and stroma, the profile of immune cell subsets on either side of the invasive margin can be quantified, specifically identification of tumour-infiltrating lymphocytes (TILs).
Significant insights can be made into the impact of immunotherapies on tumour immune processes and classification of different tumour types by direct interrogation of the tumour-immune interface.
We turn your Data into Decisions
HALO™ Digital Image Analysis
HistologiX offer assays for a range of commercially available immuno-oncology research biomarkers. Search our ever-growing list of biomarker assays below. Don’t see what you’re looking for? We can work with you to develop immuno-oncology biomarker assays for your specific biomarker. Get in touch to discuss your needs.
|Alpha smooth muscle actin antibody||Cytokeratin 10|
|Anti-PD1||Cytokeratin 18 antibody|
|Anti-PGP 9.5||Epithelial sodium channel alpha antibody|
|Bcl-xL (54H6) Rabbit mAb||ErbB 2 antibody|
|BCL2||Estrogen receptor alpha|
|Carbonic anyhydrase IX (CA9)||Fox-P3|
|CD20 antibody - C-terminal||Grelin-1|
||Human Fibroblasts (TE-7)|
|CD38 antibody (SP149) C-terminal||LC3B
|CD4||Lck (Phospho Y505)|
|CD40 antibody||Mannose receptor antibody (CD206)|
|CEBP alpha antibody||NAK/TBK1|
|CFTR antibody||Newcastle's Disease Virus|
|Cleaved caspase 3||NG2|
|CONFIRM anti-CD3 (2GV6)||Podocin|
|CONFIRM anti-CD4 (SP35)||Phospho-p38 MAPK (Thr180/Tyr182)|
|CONFIRM anti-CD45RO (UCHL-1)||Progesterone Receptor antibody|
|CONFIRM anti-CD8 (SP57)||PTEN antibody (Y184)|
|Cytokeratin 1||PTEN antibody (Y184)|
Please see our IHC biomarkers for more targets in other pathways.